How his account is checked
Each chapter is a list of claims. Load-bearing sentences are checked against a named original or a public page. The manuscript is not reprinted in full. Device-pairing and implant-construction detail is not published here.
Section 04
The account
This is how he says he found it. It is the spine of his claims. It is not itself an exhibit. Where the narrative and a scanned document disagree, the document controls.
What this site will not write
It will not write that Scripps or Richard Walker is guilty. Those are his conclusions. Official denials stay in the file. A letter that says “standard Stryker” is an exhibit. It does not close the inquiry.
Source: Folder 1, 3. Hooman Asbaghi Story.pdf, and the Google Doc “Hooman Asbaghi Story updated.” First person. Investigation notes, the 113-page first-person narrative, are used to sequence claims. They are not reprinted. Where those notes and a scan disagree, the scan controls.
He first treated Padtan Elm as the strongest piece. The medical file stays open because of thin notes, the 675/677 split, and Sheean on a 2016 lab against a later staff statement that she does not know that name. Those conflicts are documented. They are not yet a device.
Chapter 1 · 1990–1999
Early work in Iran
Claim. Palmaz-Schatz stent introductions with Bernard Valeix; Biotech Ltd.; Ghasemi trained while travel-restricted; Padtan Elm co-founded in 1995 with Farideh Kavesh, Nargues Djavad, and Alireza Amiri Gharagozloo at 25% each; ELISA kits; 1999 return to the US and a Tehran power of attorney.
On the documents. The Palmaz-Schatz calendar makes 1991–93 work in Iran possible: first coronary implant December 1987; international coronary use already underway by 1991, including Europe; U.S. iliac approval 1991; U.S. coronary PMA August 1994. That U.S. date is not a worldwide start date. Tehran hospital histories date angioplasty expansion to 1370 SH (March 1991–March 1992). Valeix is a real name on Ghasemi’s CV and on Wiktor papers — a different stent. No page in this file prints Hooman on a Palmaz-Schatz shipment. Founding paper (Docs6, 1996) names four people, not Narges. He named her as a co-founder; that claim stays his. She is an equal shareholder by October 2002, managing director by May 2012, and listed as manager of PADTAN ELM CO. on iranindustry.de. Kit photos and padtan.com Wayback from 2002 are a public footprint. The 1999 power of attorney is documented. Biotech Ltd. stays claimed until that face is on this file.
Chapter 2 · 1994–2013
Share transfer
Claim. The 1999 power of attorney was used on 14 January 2013, in a meeting he did not attend, to move assets into a new vehicle associated with Padtan Teb. Kianoosh Behlouli wrote that he was the inspector, that Farideh acted as attorney for the 250 shares, that Narges was managing director, and that he was later removed. padtanteb.ir has no archive before 2013. A later governance set (about 32 pages, 2018–2023) still shows a running company. He says he has received nothing.
On the documents. The 1999 instrument exists. Behlouli’s Farsi letter exists; it is a witness letter, not a court finding. Gazettes print him as alternate inspector; the letter heading says principal. English retellings are not the letter. The 14 January 2013 share-transfer deed is not in this file. A same-day gazette adds export language to the objects; that is not the deed. Kit inserts (AFP, H. pylori, neonatal G6PD) and padtan.com Wayback from 2002 are a public footprint. Padtan Teb’s own site copy claims 1990 and ISO 13485; Wayback’s first save for padtanteb.ir is 23 June 2013. A new website is not a new legal entity, and an unverified ISO line is a question, not a finding that they created a shell. Later minutes and share lists (2018–2022) are already on What is Padtan Elm. A data-broker revenue figure is not a filing. Iranome is a public catalog; no page currently names Padtan Elm as its maker. A recording identified as Behlouli and Narges is on the inspector door, from a timestamped transcript: he says lawyers asked about a year-92 share movement; she says she did not take action and that Ms. Kavesh can explain. The English “Report on the Content of the Voice Recording” is context, not that call. His claim that he received nothing remains unproven as to a money trail and requires more investigation.
Chapter 2.5 · 1991–2016
Ghasemi, Nipro, Nydegger
Claim. Ghasemi trained at Scripps under Teirstein then Saeed. Nipro licensed a safety-syringe patent. Nydegger malpractice: San Diego Superior Court 37-2013-00066639-CU-PN-CTL, civil jury trial heard 6 Sep 2016 at 9:00 AM, $61.6 million. A later reporter page that prints 20 Oct 2016 is a listing date, not the minute order.
On the documents. Asbaghi v. Nydegger caption and verdict date are public. Ghasemi’s CV, read off the PDF: Imam Khomeini attending; interventional fellowship Tehran University 1991–1992; France 1993; Royal Marsden 1994; Royal Brompton 1996; Scripps Clinic endovascular certificate 2003. Printed references, as written: Dr B. Valeix; M. Saeed, Head, Division of Vascular Radiology, Scripps Clinic, La Jolla; Dr Paul S. Teirstein, Head, Department of Cardiology, Scripps Clinic, La Jolla. Richard Schatz is not listed. Those lines are references, not a 1990s trainer log. The 2003 Scripps certificate is an independent match to the claim he was brought to San Diego around 2000/2003. It is not proof Hooman made the introduction. A 2002 Madayen/Bionic board page prints Hooman and Ghasemi together. Mohsin Saeed, MD, is the reasonable public identity behind “M. Saeed” on that CV — Scripps.org vascular/IR, La Jolla — and is pinned for later. A verdict against a patent lawyer is not a finding that Scripps implanted a radio.
Chapter 3 · 1993–2013
Zanetti / Gerloni / Iranome
Claim. Ommid worked in Maurizio Zanetti’s UCSD lab in the early 1990s; they dated; Zanetti met Farideh; Ghasemi became the missing academic link after the stent introduction. A Trans In’Tech LLC was set up as cover. Gerloni v. Zanetti ran for years and ended 18 days after the 14 January 2013 meeting, which he reads as a shield for covert work. Carolin Botzenhardt, later at Deutsche Bank and Wells Fargo, is alleged to have moved money and interfered with his accounts after Nydegger.
On the documents. Documentary facts first. Zanetti was a UCSD professor of medicine; Gerloni joined that lab as a postdoctoral fellow in 1993; Transgenics was a real company; Cosmo later bought that vehicle and renamed it Cosmo Bioscience. The unpublished 2013 opinion recites that sale ($18,000 to Zanetti) and that in 2005 Gerloni left UCSD to become CBI’s chief executive officer. The same opinion recites her 8 September 2006 deposition: she did not recall director status, directors’ meetings, or the specific promises in her declaration; certainty and constructive-fraud counts failed. A ResearchGate snippet still prints CEO at Cosmo Bioscience. An image result captions Cosmo Pharmaceuticals NV — a related public name, not proof the two Cosmo vehicles are one filing. A Cosmo 10-K note describes Cosmo Bioscience v. Adamis and Zanetti, filed May 2010. Nature, 13 February 1997, reported a UCSD misconduct charge that included human-experiment and biosafety-policy allegations; a later faculty panel recommended a reprimand for guideline violations while rejecting fabrication; the 2013 opinion recites a tenure-committee exoneration. Keep both. Unconsented human trials stay alleged in that 1997 reporting, not a verdict on this page. A federal court rejected Gerloni’s co-inventor claim. The California appeal was affirmed 1 February 2013. Unpublished under rule 8.1115. Eighteen days after 14 January 2013 is a calendar fact. Coordinated use of that lawsuit as a twenty-year shield, and a 3 February 2013 patent “release,” remain claimed. Iranome is a public catalog (Human Mutation 2019: 1,575,702 variants, 308,311 novel; FAQ names Illumina). Padtan Elm is not printed on those pages. Thermo Fisher closed Life Technologies on 3 February 2014, not 15 April 2013; an OEM contract is not in this file. Howard Birndorf’s public career (Hybritech, Nanogen, Illumina 1998) is web-verifiable; a 1999 wedding and a $3 million introduction are his account. Ommid working in that lab, dating Zanetti, and introducing Ghasemi for Iranian trials remains his account until a personnel page, grant, or contemporaneous letter is mounted. Trans In’Tech, LLC is a real California entity whose public officers include names from this family; “cover-up company” is the allegation, not the filing. Botzenhardt’s wealth-management titles are public and mounted under Who is Hooman. Deutsche Bank’s 2015 Iran-sanctions penalty is public and does not name her. Overlap of employer and years is overlap. A Concert for Cures host-committee graphic names her with Ommid on one printed list — continued contact, not a wire. Wells Fargo interference remains claimed. Roche dollar figures stay holdback.
Open Gerloni v. Zanetti — the opinion, Cosmo, Nature · Trans In’Tech — one company, both names · Iranome — public catalog
Chapter 4 · 2013–2017
Health decline and two hips
Claim. RF/EMF in living spaces; right THA 9 Oct 2015 and left THA 23 Oct 2017 under Walker and Schmidt, Stryker Secur-Fit / Trident / Biolox; unauthorized smart modifications; a 2015 Iran trip over a false LinkedIn CEO listing.
On the documents. Surgeries and later Stryker part lists are documented. Smart modifications remain his theory. Walker/Scripps sentences denying electronics stay on the table as sentences, not as the end of the case. Device-scan stills are not published as pairing instructions. A Scripps note names labs and a DEXA from Iran; the Iran testosterone is sourced as “patient states.” That is not a named dump from his mother’s lab.
Chapter 5 · 2016–2025
Vibration, portal gaps, discovery
Claim. Empty 26 Apr 2017 note; surgeries missing from a visit list; Walker retired/2027; Risk letter 27 May 2025; sister as Pedal co-captain; Colwell as Padres physician on his bio; Walker named president of Scripps Clinic Medical Group by 25 Jan 2017, not Scripps Health CEO in 2007–2015; Dubai accounts and a March 2025 family lawsuit.
On the documents. Portal and press faces exist. Walker’s public title is President and CEO of Scripps Clinic Medical Group, not Scripps Health the hospital system; the 2007–2015 window is not locked from the bio. Portal banner: out of office until 1/29/2027. Karches writes she has not seen him since August 2017 and does not know Sheean; a 26 Aug 2019 T4 Free still prints her as authorizing provider. Staff, quoting McGarvey: not seen in five years; a 3 Jan 2023 venous CMP still prints hers. Authorizing provider is not a visit. Dubai amounts now live on the 2024 instrument room as investigator stills and as a King & Spalding Scope of Work — not as stamped bank statements. Folder 4 and Folder 6 are one clinical file on this site. MTHFR exists; “never consented” stays alleged until a consent packet or a staff sentence says so.
Chapter 6 · 2024–2025
Dubai instrument, the suit, then the hospital
Claim. A special power of attorney in Dubai authorized inquiry into maternal UAE accounts as Padtan Elm compensation. Recovery stalled. He returned to San Diego. The family caption was filed. Vibrations lengthened. Unrecognized Bluetooth connections and meter readings near the hips are how he now reads the medical file.
On the documents. Two Dubai Courts instruments from 24 October 2024 are on this file. At 14:08 Farideh named Hooman Ali for inquiry; passports on the face. At 14:40 she named Marwan Mohamed Ahmed Noor Al-Mazmi and Ammar Ali Ahmed Ali Al-Mulla for lawsuits, settlement, and estate banking; passport and Emirates IDs on the face. Those Courts papers do not print a revocation. A 10 February 2025 Horizons & Co invoice billed to Kavish Farideh names a notarisation matter as POA revocation. Kind Attn, telephone, and IBAN are on that face. King & Spalding’s 6 December letter writes a Scope of Work of approximately $4 billion across DIB, FAB, and Emirates NBD; the countersignature here is blank. Investigator stills of FAB and Emirates NBD print very large dirham balances; the figures are covered. DIB’s 6 January 2025 letter denies a 9 December notice, addressed to Marwan Mohamed Advocates. A Chase notice prints $25,000 to NAMUS at Zand Bank on 10 January 2025. The live caption is on the court room: Asbaghi vs Asbaghi, filed 17 March 2025. One question that caption can test is whether she honored the inquiry instrument. A Mishcon de Reya note of 18 February 2026 is on Who is Farideh Kavesh. It records a call with Mr Drahmoune of Fotis Law. The copy Drahmoune said he would send is not in this file. The Scripps column holds the visit-list gap, the thin 2017 note, the conversion packet, the MyScripps thread, and a typed Stryker line — not stickers. Bluetooth Settings stills are on Phone anomalies: eight Connected and seven Connected, one of each; the CLI dump is Serial Bluetooth Terminal’s saved config, not thermostat firmware. Meter frames are not on that door yet. Where this chapter and a scan disagree, the scan controls.
Mounted original · unpublished
Gerloni v. Zanetti, filed 1 February 2013
Caption and short holding, then the Cosmo / CBI faces from the same folder. The 20-page opinion is not reprinted. California Rules of Court, rule 8.1115: not to be published in official reports. Nature 1997 is contemporaneous reporting, not a retry.